Literature DB >> 28549518

Ganglion Cell-Inner Plexiform Layer Change Detected by Optical Coherence Tomography Indicates Progression in Advanced Glaucoma.

Joong Won Shin1, Kyung Rim Sung2, Gary C Lee3, Mary K Durbin3, Daniel Cheng3.   

Abstract

PURPOSE: To examine the performance of Guided Progression Analysis (GPA; Carl Zeiss Meditec, Dublin, CA) in spectral-domain optical coherence tomography (OCT) in detecting progressive thinning of ganglion cell-inner plexiform layer (GCIPL) and retinal nerve fiber layer (RNFL) in glaucoma.
DESIGN: Longitudinal, observational study. PARTICIPANTS: A total of 196 eyes of 123 primary open-angle glaucoma patients (mean follow-up, 5.0 years).
METHODS: Macular GCIPL and peripapillary RNFL thicknesses were measured by Cirrus HD-OCT (Zeiss, Dublin, CA), and progressive GCIPL and RNFL thinning were assessed by GPA. The reference standard of glaucoma progression was determined by visual field (VF) progression. Glaucomatous eyes were classified into mild (117 eyes) or moderate to advanced (79 eyes) groups based on VF defects. Ganglion cell-inner plexiform layer and RNFL thinning rates were compared between progressors and nonprogressors. Visual field survival estimates in eyes with and without progressive GCIPL and RNFL thinning were evaluated by Kaplan-Meier survival analysis and compared with the log-rank test. MAIN OUTCOME MEASURES: Progressive GCIPL and RNFL thinning assessed by OCT GPA.
RESULTS: Seventy-six eyes (38.8%) and 43 eyes (21.9%) demonstrated progressive GCIPL and RNFL thinning, respectively, and 48 eyes (24.5%) were classified as progressors by reference standard. The rate of change in the average GCIPL thickness was significantly higher in progressors (-1.05±0.98 μm/year for mild glaucoma and -0.66±0.30 μm/year for moderate to advanced glaucoma) than in nonprogressors (-0.47±0.54 μm/year for mild glaucoma and -0.31±0.50 μm/year for moderate to advanced glaucoma), regardless of glaucoma severity (P < 0.05). Eyes with progressive GCIPL thinning had lower VF survival estimates than eyes without, regardless of glaucoma severity. However, the rate of change in the average RNFL thickness did not differ significantly in moderate to advanced glaucoma (P = 0.765; -0.26±0.55 μm/year for progressors and -0.33±0.92 μm/year for nonprogressors), and VF survival estimates did not differ significantly between eyes with and without progressive RNFL thinning in moderate to advanced glaucoma (P = 0.781).
CONCLUSIONS: Ganglion cell-inner plexiform layer GPA provides a new approach for evaluating glaucoma progression. It may be more useful for detecting progression in the advanced stages of glaucoma than RNFL GPA.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28549518     DOI: 10.1016/j.ophtha.2017.04.023

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  32 in total

1.  Measurement Floors and Dynamic Ranges of OCT and OCT Angiography in Glaucoma.

Authors:  Sasan Moghimi; Christopher Bowd; Linda M Zangwill; Rafaella C Penteado; Kyle Hasenstab; Huiyuan Hou; Elham Ghahari; Patricia Isabel C Manalastas; James Proudfoot; Robert N Weinreb
Journal:  Ophthalmology       Date:  2019-03-08       Impact factor: 12.079

2.  Analysis of macular microvasculature and thickness after ICL implantation in patients with myopia using optical coherence tomography.

Authors:  Qiu-Jian Zhu; Meng-Yu Wang; Peng Yu; Xiao-Suo Liang; Lie Ma; Hai-Xiang Xiao; You Yuan
Journal:  Int J Ophthalmol       Date:  2020-12-18       Impact factor: 1.779

3.  Serial Combined Wide-Field Optical Coherence Tomography Maps for Detection of Early Glaucomatous Structural Progression.

Authors:  Won June Lee; Tai Jun Kim; Young Kook Kim; Jin Wook Jeoung; Ki Ho Park
Journal:  JAMA Ophthalmol       Date:  2018-10-01       Impact factor: 7.389

4.  Progression of Primary Open-Angle Glaucoma in Diabetic and Nondiabetic Patients.

Authors:  Huiyuan Hou; Takuhei Shoji; Linda M Zangwill; Sasan Moghimi; Luke J Saunders; Kyle Hasenstab; Elham Ghahari; Patricia Isabel C Manalastas; Tadamichi Akagi; Mark Christopher; Rafaella C Penteado; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2018-02-13       Impact factor: 5.258

5.  Association of Macular and Circumpapillary Microvasculature with Visual Field Sensitivity in Advanced Glaucoma.

Authors:  Elham Ghahari; Christopher Bowd; Linda M Zangwill; James Proudfoot; Kyle A Hasenstab; Huiyuan Hou; Rafaella C Penteado; Patricia Isabel C Manalastas; Sasan Moghimi; Takuhei Shoji; Mark Christopher; Adeleh Yarmohammadi; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2019-03-14       Impact factor: 5.258

6.  Focal alteration of the intraretinal layers in neurodegenerative disorders.

Authors:  Shriya Airen; Ce Shi; Zhiping Liu; Bonnie E Levin; Joseph F Signorile; Jianhua Wang; Hong Jiang
Journal:  Ann Eye Sci       Date:  2020-03

Review 7.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

8.  Can Macula and Optic Nerve Head Parameters Detect Glaucoma Progression in Eyes with Advanced Circumpapillary Retinal Nerve Fiber Layer Damage?

Authors:  Fabio Lavinsky; Mengfei Wu; Joel S Schuman; Katie A Lucy; Mengling Liu; Youngseok Song; Julia Fallon; Maria de Los Angeles Ramos Cadena; Hiroshi Ishikawa; Gadi Wollstein
Journal:  Ophthalmology       Date:  2018-06-19       Impact factor: 12.079

9.  Review of Longitudinal Glaucoma Progression: 5 Years after the Shaffer Lecture.

Authors:  Joel S Schuman; Tigran Kostanyan; Igor Bussel
Journal:  Ophthalmol Glaucoma       Date:  2019-12-02

10.  Evaluation of a Region-of-Interest Approach for Detecting Progressive Glaucomatous Macular Damage on Optical Coherence Tomography.

Authors:  Zhichao Wu; Denis S D Weng; Abinaya Thenappan; Robert Ritch; Donald C Hood
Journal:  Transl Vis Sci Technol       Date:  2018-03-29       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.